Superselective intra-arterial chemoradiotherapy with docetaxel-nedaplatin for advanced oral cancer
Superselective intra-arterial chemoradiotherapy with docetaxel-nedaplatin for advanced oral cancer
复制标题
DOI：
10.1016/j.oraloncology.2010.10.001
复制
发表时间：
2010-12-01
期刊：
影响因子：
4.8
通讯作者：
Nagahata, Morio
中科院分区：
文献类型：
--
作者：
Kobayashi, Wataru;Teh, Beng Gwan;Nagahata, Morio
以顺铂为基础的超选择性动脉内化疗联合放疗（SSIACRT）作为晚期头颈部癌的常用/治愈性治疗已得到广泛接受。我们在2003年将奈达铂（CDGP）与多西他赛（DOC）联合作为SSIACRT治疗晚期口腔鳞状细胞癌的新组合。2003年至2009年，22例晚期口腔癌患者接受放疗（66戈伊），同时超选择动脉内DOC（40 mg/体）和CDGP（80 mg/m2）输注。22例患者中有18例（81.8%）达到完全缓解。在17例颈部疾病阳性的患者中，16例（94%）被评估为无病。5年生存率为78.5%，主要不良反应为白细胞减少和粘膜炎。5例（22.7%）患者在治疗后发生远处转移，这些结果表明动脉内灌注紫杉醇-奈达铂联合放疗对晚期口腔癌是有效的。副作用很容易控制，治疗的最重要结果是保持患者的生活质量（QOL）和改善预后。(C)2010爱思唯尔有限公司保留所有权利。
Cisplatin-based, superselective, intra-arterial chemotherapy concurrent with radiotherapy (SSIACRT) has gained wide acceptance as a common/curative treatment for advanced head and neck cancer. We combined nedaplatin (CDGP) with docetaxel (DOC) as a new combination in SSIACRT for advanced oral squamous cell carcinoma in 2003. Twenty-two patients with advanced oral cancer were treated by radiotherapy (66 Gy) concurrent with superselective intra-arterial DOC (40 mg/body) and CDGP (80 mg/m(2)) infusion between 2003 and 2009. Complete response was achieved in 18 (81.8%) of the 22 patients. Of the 17 patients with positive neck disease, 16 (94%) were assessed as disease-free. The 5-year overall survival rate was 78.5%, and the major adverse effects were leukocytopenia and mucositis. Five patients (22.7%) developed distant metastases post-treatment.These results indicate that intra-arterial docetaxel-nedaplatin infusion concurrent with radiotherapy is efficacious for advanced oral cancer. The side effects are easily manageable, and the most important outcome of the treatment is the preservation of patients' quality of life (QOL) and improved prognosis. (C) 2010 Elsevier Ltd. All rights reserved.